[Interaction of salicyl compounds and other non-steroidal anti-inflammatory agents: pharmacokinetic study of phenylbutazone-aspirin combination in man].
The pharmacodynamic interaction between phenybutazone and aspirin was studied in 9 patients. The levels of phenylbutazone were estimated by gas-chromatography and verified by mass-spectrometry. When phenylbutazone was administered together with salicylates a decrease in the bioavailability of phenylbutazone was demonstrated, but there was no significant variation in the absorption and elimination constants or in the half-life. The variations were much less than those observed with other nonsteroid anti-inflammatory drugs (indometacine, naproxen, fenoprofen). These interactions must be taken into account in the long-term treatment of cases of inflammatory rheumatism.
D000328:Adult; D001241:Aspirin / Q000378:metabolism / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004336:Drug Antagonism; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000378:metabolism / Q000494:pharmacology*
D010653:Phenylbutazone; D001241:Aspirin
A propos des interactions des salicylés et des autres anti-inflammatoires non stéroidiens; etude pharmacocinétique de l'association phénylbutazone-aspirine chez l'homme